Skip to main content
. 2024 Apr 10;20(22):1587–1600. doi: 10.2217/fon-2023-0301

Figure 2.

Figure 2.

Evidence networks with KEYNOTE-355 patients assigned to nab-paclitaxel, paclitaxel and gemcitabine/carboplatin analyzed separately (scenario 1).

Cohorts of patients receiving nab-paclitaxel (A), paclitaxel (B), or gemcitabine/carboplatin (C) in KEYNOTE-355 were analyzed in separate networks, as these treatments were assumed to have different efficacies. Due to a lack of common comparators, the networks are disconnected.